Literature DB >> 23918747

De novo complex X chromosome rearrangement unmasking maternally inherited CSF2RA deletion in a girl with pulmonary alveolar proteinosis.

Julie Auger1, Céline Bonnet, Mylène Valduga, Christophe Philippe, Emmanuelle Bertolo-Houriez, Mylène Beri-Dexheimer, Cyril Schweitzer, Bruno Leheup, Philippe Jonveaux.   

Abstract

We report on a 3-year-old girl with a de novo complex X chromosome rearrangement associated with congenital pulmonary alveolar proteinosis (PAP) and short stature. Array comparative genome hybridization and FISH analyses contributed to characterize the complex rearrangement consisting of a 7.37 Mb terminal deletion of Xp22.33p22.2, a 17.3 Mb interstitial inverted duplication of Xp22.2p21.3, and a 10.14 Mb duplication of Xq27.3q28. PCR analysis of microsatellite markers supported a paternal origin of the X chromosome rearrangement. A pre-meiotic two-step mechanism may explain the occurrence of this complex X rearrangement: an inverted duplication deletion event on Xp, and duplication of the Xq27.3qter region through a telomere capture event stabilizing the broken chromosome Xp end. The girl has also inherited from her healthy mother an X chromosome with a colony stimulating factor 2 receptor, alpha (CSF2RA) gene deletion. Consistent with the recessive mode of inheritance, the de novo paternal Xp22.33p22.2 deletion combined to the maternally inherited CSF2RA gene deletion led to homozygous deletion of CSF2RA and PAP diagnosis in the girl. The Xp deletion encompasses the pseudoautosomal region 1 (PAR1) which contains genes that escape X inactivation. Short stature homeobox (SHOX) haploinsufficiency explains growth retardation. Absence of other symptoms in relation to the X deletion/amplification is most probably due to skewed X inactivation. Finally, inherited deletions may unmask rare pathogenic genomic rearrangement and contribute to clinical phenotypes by a recessive mode of gene action.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  CSF2RA; array comparative genome hybridization; congenital pulmonary alveolar proteinosis; inv dup del Xp

Mesh:

Substances:

Year:  2013        PMID: 23918747     DOI: 10.1002/ajmg.a.36097

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  6 in total

Review 1.  Pulmonary alveolarproteinosis in children.

Authors:  Andrew Bush; Rishi Pabary
Journal:  Breathe (Sheff)       Date:  2020-06

Review 2.  Mechanisms of Origin, Phenotypic Effects and Diagnostic Implications of Complex Chromosome Rearrangements.

Authors:  Martin Poot; Thomas Haaf
Journal:  Mol Syndromol       Date:  2015-08-15

3.  Complex X chromosome rearrangement associated with multiorgan autoimmunity.

Authors:  Irén Haltrich; Henriett Pikó; Horolma Pamjav; Anikó Somogyi; Antónia Völgyi; Dezső David; Artúr Beke; Zoltán Garamvölgyi; Eszter Kiss; Veronika Karcagi; György Fekete
Journal:  Mol Cytogenet       Date:  2015-07-19       Impact factor: 2.009

4.  Characterization of CSF2RA mutation related juvenile pulmonary alveolar proteinosis.

Authors:  Jenna Hildebrandt; Ebru Yalcin; Hans-Georg Bresser; Guzin Cinel; Monika Gappa; Alireza Haghighi; Nural Kiper; Soheila Khalilzadeh; Karl Reiter; John Sayer; Nicolaus Schwerk; Anke Sibbersen; Sabine Van Daele; Georg Nübling; Peter Lohse; Matthias Griese
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

5.  Whole-Genome Sequencing of a Family with Hereditary Pulmonary Alveolar Proteinosis Identifies a Rare Structural Variant Involving CSF2RA/CRLF2/IL3RA Gene Disruption.

Authors:  Chih-Yung Chiu; Shih-Chi Su; Wen-Lang Fan; Shen-Hao Lai; Ming-Han Tsai; Shih-Hsiang Chen; Kin-Sun Wong; Wen-Hung Chung
Journal:  Sci Rep       Date:  2017-02-24       Impact factor: 4.379

6.  Cryptic breakpoint identified by whole-genome mate-pair sequencing in a rare paternally inherited complex chromosomal rearrangement.

Authors:  Constantia Aristidou; Athina Theodosiou; Andria Ketoni; Mads Bak; Mana M Mehrjouy; Niels Tommerup; Carolina Sismani
Journal:  Mol Cytogenet       Date:  2018-06-07       Impact factor: 2.009

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.